Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.74 |
| ▸ | TYK2 | P29597 | 18/20 | 0.62 |
| ▸ | JAK1 | P23458 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24776107 | 1.00 | JAK2 (0.74) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL24775864 | 0.89 | JAK2 (0.75) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL29947332 | 0.89 | JAK2 (0.75) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL31280405 | 0.86 | JAK2 (0.56) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL27172593 | 0.86 | JAK2 (0.60) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL31280961 | 0.85 | JAK2 (0.54) | JAK2TYK2JAK1CYP2C19 | |
| SCHEMBL31280222 | 0.85 | TYK2 (0.56) | JAK2TYK2JAK1CYP2C19 | |
| Envucitinib SCHEMBL22647242 | 0.85 | JAK2 (1.00) | JAK2TYK2JAK1 | |
| Envucitinib SCHEMBL31369047 | 0.85 | JAK2 (1.00) | JAK2TYK2JAK1 | |
| SCHEMBL24782774 | 0.85 | JAK2 (0.69) | JAK2TYK2JAK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337648-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4337648-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2022241174-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4337648-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117355514-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022241174-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |